Metagenomi (MGX) Stock: Buy, Sell, or Hold?
MGX - Metagenomi, Inc. Common Stock
$1.17
0.01 (0.86%)
▲
5d:
-1.68%
30d:
-5.65%
90d:
-8.59%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When MGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MGX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MGX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MGX is currently trading at $1.17, which is considered oversold relative to its 30-day fair value range of $1.19 to $1.23.
Technical Outlook: Technically, MGX is in a strong downtrend. Immediate support is located at $1.13, while resistance sits at $1.25.
Market Sentiment: MGX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+498.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MGX is in a strong downtrend. Immediate support is located at $1.13, while resistance sits at $1.25.
Market Sentiment: MGX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+498.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.19 -
$1.23
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 498.3% below Wall St target ($7.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.19 -
$1.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.13
Resistance Level
$1.25
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.64
Wall Street Target
$7.00
(+498.3%)
Revenue Growth (YoY)
-69.8%
Share & Embed Analysis
Last updated: September 07, 2026 4:30 AM ET
Data refreshes hourly during market hours. Next update: 5:30 AM
Data refreshes hourly during market hours. Next update: 5:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 46 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 26 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 40 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$59 | 64 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 36 SELL |
